Clinical Trials / Research Studies
Craniopharyngioma

Craniopharyngioma

CONNECT1905: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

  • Ages: 1 Year to 25 Years

Adamantinomatous Craniopharyngioma (ACP) is a highly debilitating pediatric brain tumor that lacks medical anti-tumor therapies. Current therapy, which depends largely on surgery and radiation, is associated with poor quality of life and becomes more challenging and risky in the setting of recurrent ...More